| Moore Foot & Ankle Specialists, Pa | |
|
136 Mimosa Dr, Asheville, NC 28806-1719 | |
| (828) 350-1880 | |
| (828) 252-2272 |
| Full Name | Moore Foot & Ankle Specialists, Pa |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 136 Mimosa Dr, Asheville, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225195746 | NPI | - | NPPES |
| 016A1 | Other | NC | BCBS |
| 89016MW | Medicaid | NC |
| Provider Name | Lily L Moore |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1609943703 PECOS PAC ID: 0648163360 Enrollment ID: I20040210001173 |
News Archive
Skilled Healthcare Group, Inc. today reported that a jury in Humboldt County, California, returned a verdict against the Company related to a complaint filed more than four years ago. The case has been disclosed in the Company's prior Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.
GE Healthcare, a unit of the General Electric Company, today presented interim phase 2 study results of fluciclatide, in collaboration with the National Cancer Institute, a federal research agency and part of the National Institutes of Health. Fluciclatide is an integrin-targeted radiopharmaceutical under development for oncology PET imaging.
Astellas Pharma Inc. and XenoPort, Inc. announced today that Regnite (gabapentin enacarbil) Extended-Release Tablets will be launched in Japan on July 10, 2012. Regnite is approved in Japan for the treatment of moderate-to-severe primary restless legs syndrome (RLS).
Reporting for Kaiser Health News, Maggie Mertens writes: "State regulators are cracking down on a health care product that targets the growing group of uninsured and underinsured Americans: the discount health plan" (Mertens, 4/29).
Meanwhile, among the many ballot items across the country, Florida voters rejected an effort to block some of the federal health law's requirements and limits on abortion. But voters in Alabama, Missouri and Wyoming approved measures to curb the reach of the health law.
› Verified 2 days ago
| Provider Name | John Christopher Moore |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1790852895 PECOS PAC ID: 5294715918 Enrollment ID: I20040722001385 |
News Archive
Skilled Healthcare Group, Inc. today reported that a jury in Humboldt County, California, returned a verdict against the Company related to a complaint filed more than four years ago. The case has been disclosed in the Company's prior Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.
GE Healthcare, a unit of the General Electric Company, today presented interim phase 2 study results of fluciclatide, in collaboration with the National Cancer Institute, a federal research agency and part of the National Institutes of Health. Fluciclatide is an integrin-targeted radiopharmaceutical under development for oncology PET imaging.
Astellas Pharma Inc. and XenoPort, Inc. announced today that Regnite (gabapentin enacarbil) Extended-Release Tablets will be launched in Japan on July 10, 2012. Regnite is approved in Japan for the treatment of moderate-to-severe primary restless legs syndrome (RLS).
Reporting for Kaiser Health News, Maggie Mertens writes: "State regulators are cracking down on a health care product that targets the growing group of uninsured and underinsured Americans: the discount health plan" (Mertens, 4/29).
Meanwhile, among the many ballot items across the country, Florida voters rejected an effort to block some of the federal health law's requirements and limits on abortion. But voters in Alabama, Missouri and Wyoming approved measures to curb the reach of the health law.
› Verified 2 days ago
| Provider Name | Meredith L Ward |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1124433982 PECOS PAC ID: 1759667215 Enrollment ID: I20170418000161 |
News Archive
Skilled Healthcare Group, Inc. today reported that a jury in Humboldt County, California, returned a verdict against the Company related to a complaint filed more than four years ago. The case has been disclosed in the Company's prior Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.
GE Healthcare, a unit of the General Electric Company, today presented interim phase 2 study results of fluciclatide, in collaboration with the National Cancer Institute, a federal research agency and part of the National Institutes of Health. Fluciclatide is an integrin-targeted radiopharmaceutical under development for oncology PET imaging.
Astellas Pharma Inc. and XenoPort, Inc. announced today that Regnite (gabapentin enacarbil) Extended-Release Tablets will be launched in Japan on July 10, 2012. Regnite is approved in Japan for the treatment of moderate-to-severe primary restless legs syndrome (RLS).
Reporting for Kaiser Health News, Maggie Mertens writes: "State regulators are cracking down on a health care product that targets the growing group of uninsured and underinsured Americans: the discount health plan" (Mertens, 4/29).
Meanwhile, among the many ballot items across the country, Florida voters rejected an effort to block some of the federal health law's requirements and limits on abortion. But voters in Alabama, Missouri and Wyoming approved measures to curb the reach of the health law.
› Verified 2 days ago
| Provider Name | Amanda Pless |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1336513845 PECOS PAC ID: 3072869643 Enrollment ID: I20180712000753 |
News Archive
Skilled Healthcare Group, Inc. today reported that a jury in Humboldt County, California, returned a verdict against the Company related to a complaint filed more than four years ago. The case has been disclosed in the Company's prior Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.
GE Healthcare, a unit of the General Electric Company, today presented interim phase 2 study results of fluciclatide, in collaboration with the National Cancer Institute, a federal research agency and part of the National Institutes of Health. Fluciclatide is an integrin-targeted radiopharmaceutical under development for oncology PET imaging.
Astellas Pharma Inc. and XenoPort, Inc. announced today that Regnite (gabapentin enacarbil) Extended-Release Tablets will be launched in Japan on July 10, 2012. Regnite is approved in Japan for the treatment of moderate-to-severe primary restless legs syndrome (RLS).
Reporting for Kaiser Health News, Maggie Mertens writes: "State regulators are cracking down on a health care product that targets the growing group of uninsured and underinsured Americans: the discount health plan" (Mertens, 4/29).
Meanwhile, among the many ballot items across the country, Florida voters rejected an effort to block some of the federal health law's requirements and limits on abortion. But voters in Alabama, Missouri and Wyoming approved measures to curb the reach of the health law.
› Verified 2 days ago
| Provider Name | Trusha Jariwala |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1932631298 PECOS PAC ID: 4587939103 Enrollment ID: I20200707002095 |
News Archive
Skilled Healthcare Group, Inc. today reported that a jury in Humboldt County, California, returned a verdict against the Company related to a complaint filed more than four years ago. The case has been disclosed in the Company's prior Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.
GE Healthcare, a unit of the General Electric Company, today presented interim phase 2 study results of fluciclatide, in collaboration with the National Cancer Institute, a federal research agency and part of the National Institutes of Health. Fluciclatide is an integrin-targeted radiopharmaceutical under development for oncology PET imaging.
Astellas Pharma Inc. and XenoPort, Inc. announced today that Regnite (gabapentin enacarbil) Extended-Release Tablets will be launched in Japan on July 10, 2012. Regnite is approved in Japan for the treatment of moderate-to-severe primary restless legs syndrome (RLS).
Reporting for Kaiser Health News, Maggie Mertens writes: "State regulators are cracking down on a health care product that targets the growing group of uninsured and underinsured Americans: the discount health plan" (Mertens, 4/29).
Meanwhile, among the many ballot items across the country, Florida voters rejected an effort to block some of the federal health law's requirements and limits on abortion. But voters in Alabama, Missouri and Wyoming approved measures to curb the reach of the health law.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Moore Foot & Ankle Specialists, Pa 136 Mimosa Dr, Asheville, NC 28806-1719 Ph: (828) 350-1880 | Moore Foot & Ankle Specialists, Pa 136 Mimosa Dr, Asheville, NC 28806-1719 Ph: (828) 350-1880 |
News Archive
Skilled Healthcare Group, Inc. today reported that a jury in Humboldt County, California, returned a verdict against the Company related to a complaint filed more than four years ago. The case has been disclosed in the Company's prior Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.
GE Healthcare, a unit of the General Electric Company, today presented interim phase 2 study results of fluciclatide, in collaboration with the National Cancer Institute, a federal research agency and part of the National Institutes of Health. Fluciclatide is an integrin-targeted radiopharmaceutical under development for oncology PET imaging.
Astellas Pharma Inc. and XenoPort, Inc. announced today that Regnite (gabapentin enacarbil) Extended-Release Tablets will be launched in Japan on July 10, 2012. Regnite is approved in Japan for the treatment of moderate-to-severe primary restless legs syndrome (RLS).
Reporting for Kaiser Health News, Maggie Mertens writes: "State regulators are cracking down on a health care product that targets the growing group of uninsured and underinsured Americans: the discount health plan" (Mertens, 4/29).
Meanwhile, among the many ballot items across the country, Florida voters rejected an effort to block some of the federal health law's requirements and limits on abortion. But voters in Alabama, Missouri and Wyoming approved measures to curb the reach of the health law.
› Verified 2 days ago
Asheville Podiatry Associates Pa Podiatrist Medicare: Medicare Enrolled Practice Location: 417 Biltmore Ave, Suite 3g, Asheville, NC 28801 Phone: 828-252-9424 Fax: 828-251-1301 | |
Debra J Wright, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 417 Biltmore Ave, Doctors Park, Suite 3g, Asheville, NC 28801 Phone: 828-252-9424 Fax: 828-251-1301 | |
Meredith Ward Dickson, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 136 Mimosa Dr, Asheville, NC 28806 Phone: 828-350-1880 Fax: 828-252-2272 | |
Smoky Mountain Foot Clinic Pa Podiatrist Medicare: Medicare Enrolled Practice Location: 573 Merrimon Ave, Asheville, NC 28804 Phone: 828-254-7716 | |
Dr. Matthew R Sheedy, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1 Vanderbilt Park Dr Ste 100, Asheville, NC 28803 Phone: 828-277-8042 Fax: 828-277-8046 | |
Dr. Amanda Lee Pless, D.P.M. Podiatrist Medicare: May Accept Medicare Assignments Practice Location: 136 Mimosa Dr, Asheville, NC 28806 Phone: 828-350-1880 Fax: 828-252-2272 |